Hims & Hers Posts Q1 Loss, Misses Revenue With Weaker EBITDA Outlook
Hims & Hers Health reported first-quarter revenue of $608.1 million, missing estimates of $616.9 million, and a net loss of $92.1 million compared with net income of $49.5 million a year earlier, amid increasing competition in the weight-loss drug market. Adjusted EBITDA fell to $44.3 million from $91.1 million and gross margin narrowed to 65% from 73%, even as subscribers rose 9% to nearly 2.6 million.
For the second quarter, Hims forecast revenue of $680 million to $700 million, above estimates, but adjusted EBITDA of $35 million to $55 million, below expectations. Its CFO said the company expects to return to profitability in 2027 after first-quarter write-downs tied to compounding GLP-1 ingredients and inventory, plus one-time M&A costs, while reiterating 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
From the sources (5 posts)
@wallstengine$HIMS Q1’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $608.1M (Est. $616.9M) 🔴; +4% YoY 🔹 Net Loss: $92.1M 🔹 Subscribers: Nearly 2.6M; +9% YoY 🔹 Monthly Revenue Per Avg. Subscriber: $80; -6% YoY FY Guide: 🔹 Adj. EBITDA: $275M-$350M (Est. $322.8M) 🟡
@stocksavvyshay$HIMS Q1 EARNINGS • Revenue $608M vs Est. $618M • EPS ($0.40) vs Est. $0.02 • EBITDA $44M vs Est. $46M • Gross Margin: 65% vs Est. 72% • Subscribers $2.6M vs Est. $2.6M Q2 Guidance • Revenue $690M vs Est. $645M • EBITDA $45M vs Est. $70M
@businessHims & Hers Health reported a first-quarter loss and sales that missed Wall Street estimates amid increasing competition in the weight-loss drug market
@wallstengine$HIMS CFO expects the company to return to profitability in 2027 after Q1 was hit by write-downs tied to compounding GLP-1 ingredients and inventory, plus one-time M&A costs.
@stocksavvyshay$HIMS reiterated its 2030 targets with “high conviction” in reaching at least $6.5B of revenue. The long-term guide also calls for at least $1.3B of adjusted EBITDA by 2030.